magrolimab + nivolumab + FOLFOX + cetuximab

This is a four-drug regimen combining **magrolimab** (a monoclonal antibody against CD47), **nivolumab** (a PD-1 immune checkpoint inhibitor monoclonal antibody), **FOLFOX** (a chemotherapy regimen containing folinic acid [leucovorin], fluorouracil [5-FU], and oxaliplatin), and **cetuximab** (an anti-EGFR monoclonal antibody). This combination is under investigation for use in advanced or recurrent colorectal cancer, particularly aiming to enhance antitumor immune response and chemotherapy efficacy in a synergistic manner[1][3]. Magrolimab blocks the "don't eat me" signal on cancer cells, promoting phagocytosis. Nivolumab promotes T-cell mediated immune responses. FOLFOX exerts cytotoxic effects on rapidly dividing cells. Cetuximab inhibits EGFR signaling, limiting tumor growth and contributing immunomodulatory effects.